• Patent granted by Canadian Intellectual Property Office
• Protects AD-214 composition of matter in major commercial markets
• Completes global patent protection for AD-214 until 2036

AdAlta Limited (ASX:1AD), a developer of next-generation cell and protein therapeutic products, has announced that it has been granted a new composition of matter patent relating to its first-in-class anti-fibrotic product, AD-214, by the Canadian Intellectual Property Office. The patent, Canadian Patent Number 2,973,317, entitled 'CXCR4 binding molecules', has an expiry date of 8 January 2036. This patent protects the i-body sequence used in AD-214, as well as similar sequences, pharmaceutical compositions and derivatives containing these i-body sequences, and the use of these sequences in therapeutic and diagnostic applications, including Idiopathic Pulmonary Fibrosis (IPF) and kidney fibrosis. With this new patent, AD-214 is now protected by composition of matter patents in all major commercial markets, including the US, Canada, European Union, and Japan, as well as key potential manufacturing locations such as India and China. AdAlta has also made applications for additional patents related to dosing and methods of treatment that, if granted, would provide further protection until 2043.